KRAS
Histopathology Overview / Directory
Purpose of the test
KRAS mutations, which are found in 30% to 45% of all colorectal tumors, are excellent indicators of which patients will benefit from the addition of cetuximab, a drug which targets epidermal growth factor receptor (EGFR). If KRAS, a gene which is located upstream of EGFR, is mutated then patients are unlikely to respond to this drug as they will have no functional EGFR.
Testing for this particular mutation defines the predicted response to this drug. A recent study showed that combination therapy which included cetuximab reduced the risk for metastatic colorectal cancer growth or spread by 15%. KRAS mutation analysis is now therefore a standard of care necessary for all newly diagnosed CRCs.
Sample Requirements
Paraffin processed blocks or sections of tumour.
Tissue that has been decalcified in acid is not suitable.
Storage and Transport
First class post within 4 days (temperature not to exceed 30°C during transport)
Turnaround Time
2 – 3 Weeks
Price
Price available on application - please contact adrianturner1@nhs.net. Discounts could be available for significant workloads.
Contacts
Jane Moorhead
T 020 3299 3091
Dr J Salisbury, Consultant Histopathologist and Departmental Head of Service
T 020 3299 3093
